Cargando…

Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Clostridioides difficile Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis

Fecal microbiota transplantation (FMT) has been shown to be an effective treatment for recurrent Clostridioides difficile infections (rCDIs). We assessed the benefits of a multidisciplinary C. difficile clinic for screening FMT eligibility in patients with rCDI. Patients seen at the University of Vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Jae Hyun, Chaplin, Ashley S., Hays, R. Ann, Kolling, Glynis L., Vance, Sheila, Guerrant, Richard L., Archbald-Pannone, Laurie, Warren, Cirle A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678700/ https://www.ncbi.nlm.nih.gov/pubmed/31315214 http://dx.doi.org/10.3390/jcm8071036

Ejemplares similares

1211. Response to Fecal Microbiota Transplant (FMT) in Refractory Clostridioides difficile Infection (CDI) is Modest Compared to Recurrent CDI in Hospitalized Patients
por: Shin, Jae Hyun, et al.
Publicado: (2020)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

Hospitalized Older Patients with Clostridioides difficile Infection Refractory to Conventional Antibiotic Therapy Benefit from Fecal Microbiota Transplant
por: Shin, Jae Hyun, et al.
Publicado: (2021)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Long-term Care Resident Quality of Life 1 Year Following Initial COVID-19 Vaccination
por: Ryall, Amy, et al.
Publicado: (2023)

Alanyl-glutamine supplementation for Clostridioides difficile infection treatment (ACT): a double-blind randomised controlled trial study protocol
por: Warren, Cirle A, et al.
Publicado: (2023)

Survey of C. difficile-Specific Infection Control Policies in Local Long-Term Care Facilities
por: Archbald-Pannone, Laurie
Publicado: (2014)

S100B Inhibition Attenuates Intestinal Damage and Diarrhea Severity During Clostridioides difficile Infection by Modulating Inflammatory Response
por: Costa, Deiziane V. S., et al.
Publicado: (2021)

Adenosine A(2A) receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment
por: Li, Yuesheng, et al.
Publicado: (2012)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Clostridioides difficile colonization among very young children in resource-limited settings
por: Brennhofer, Stephanie A., et al.
Publicado: (2022)

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019)

Fecal microbiota transplantation beyond Clostridioides difficile infections
por: Wortelboer, Koen, et al.
Publicado: (2019)

Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection
por: Moon, Chang Mo, et al.
Publicado: (2021)

Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Soveral, Lucas F, et al.
Publicado: (2022)

Clostridioides difficile Infection in the Neurorehabilitation Setting: Importance of a Multidisciplinary Approach and Impact of the Fecal Microbiota Transplantation
por: Secondo, Daniela, et al.
Publicado: (2023)

Network analysis of toxin production in Clostridioides difficile identifies key metabolic dependencies
por: Powers, Deborah A., et al.
Publicado: (2023)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile
por: Jan, N., et al.
Publicado: (2021)

Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Björkqvist, Olle, et al.
Publicado: (2021)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
por: Huus, Kelsey E, et al.
Publicado: (2020)

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients
por: Ali, Hiba, et al.
Publicado: (2021)

792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Boton, Noah, et al.
Publicado: (2020)

Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease
por: Meighani, Alireza, et al.
Publicado: (2020)

Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection
por: Cho, Young-Seok
Publicado: (2021)

Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
por: Yoon, Hyuk, et al.
Publicado: (2021)

Ischemic colitis complicated by Clostridioides difficile infection treated with fecal microbiota transplantation
por: Kang, Seok Hyung, et al.
Publicado: (2023)

Correction to Glynis L. Kolling et al., Gut Microbes Volume 3, Issue 6; pp. 523–9
por: Kolling, Glynis L., et al.
Publicado: (2013)

697. Outcomes of Tigecycline Use for Clostridioides difficile Infection: A Case Series of 28 Patients
por: Phillips, Emma C, et al.
Publicado: (2021)

709. Post-Clostridioides difficile Infection Neuroinflammatory Response in an Animal Model
por: Yang, Suemin E, et al.
Publicado: (2023)

Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes
por: Madden, Gregory R., et al.
Publicado: (2022)

Dielectrophoretic Monitoring and Interstrain Separation of Intact Clostridium difficile Based on Their S(Surface)-Layers
por: Su, Yi-Hsuan, et al.
Publicado: (2014)

Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Steed, Danielle Barrios, et al.
Publicado: (2020)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality
por: Boone, J. H., et al.
Publicado: (2014)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation
por: Bachour, Salam P., et al.
Publicado: (2023)

Interactions Between Clostridioides difficile and Fecal Microbiota in in Vitro Batch Model: Growth, Sporulation, and Microbiota Changes
por: Horvat, Sabina, et al.
Publicado: (2018)

Clinical response and changes in the fecal microbiota and metabolite levels after fecal microbiota transplantation in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection
por: Osaki, Hayato, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mjfrnh8oqq2rf7d44fmnud06ap